8-K: Indaptus Therapeutics Regains Nasdaq Listing Compliance, Averting Delisting Threat

Indaptus Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a prior deficiency and securing its listing.

Summary

• Indaptus Therapeutics, Inc. (INDP) received notification on July 14, 2025, from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price.
• The company's common stock maintained a closing bid price of $1.00 per share or greater for 10 consecutive business days, from June 27, 2025, to July 11, 2025.
• This action successfully resolves the previously reported non-compliance issue, which was initially notified on January 31, 2025.
• Nasdaq now considers the prior bid price deficiency matter closed, eliminating the immediate threat of delisting from The Nasdaq Capital Market.

Sentiment

Score: 8

Explanation: The resolution of a delisting threat is a significant positive event for the company and its shareholders, removing a major overhang and stabilizing its market presence. It indicates a positive step in addressing a critical operational risk.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement, eliminating the immediate risk of delisting from The Nasdaq Capital Market.
• The company's common stock maintained a closing bid price of $1.00 or greater for the required 10 consecutive business days, demonstrating a recovery in share price.
• Nasdaq has officially closed the prior bid price deficiency matter, providing certainty regarding the company's listing status.

Negatives

• The company was previously non-compliant with Nasdaq's minimum bid price requirement, indicating past stock price weakness and potential investor concern.
• The stock price had fallen below the $1.00 threshold, triggering the initial non-compliance notification and creating uncertainty.

Risks

• Risk of future non-compliance with Nasdaq listing rules if the common stock's bid price falls below $1.00 again for an extended period.
• Potential for continued volatility in the company's stock price, which could lead to future compliance challenges.

Future Outlook

The matter regarding the minimum bid price deficiency is now considered closed by Nasdaq, indicating that Indaptus Therapeutics, Inc. has successfully resolved the non-compliance issue and is currently in good standing with the Nasdaq listing requirements. This removes an immediate operational and financial overhang.

Management Comments

• The company has duly caused this report to be signed on its behalf by Nir Sassi, Chief Financial Officer, confirming the accuracy and official nature of the compliance update.

Industry Context

Maintaining a listing on a major exchange like Nasdaq is crucial for biotechnology companies such as Indaptus Therapeutics, as it provides essential access to capital markets, enhances liquidity for investors, and maintains corporate visibility and credibility. Failure to meet listing standards can severely impact a company's ability to raise funds for research and development, and its overall public perception.

Stakeholder Impact

• Shareholders: The resolution of the compliance issue removes the immediate threat of delisting, which could have negatively impacted share liquidity, investor confidence, and the ability to trade on a major exchange.
• Investors: Provides clarity and stability regarding the company's listing status on a major exchange, potentially reducing uncertainty.

Next Steps

• Continue to monitor the common stock's bid price to ensure ongoing compliance with Nasdaq listing rules and prevent future deficiencies.

Key Dates

Recommendation

Keywords

Indaptus Therapeutics, INDP, Nasdaq, Listing Compliance, Minimum Bid Price, 8-K Filing, Stock Market, Biotechnology, SEC Filing